Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Name: Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
License: Public Domain

BinYong Liang

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

hepatocellular-carcinoma

hepatocellular carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 127603
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.